Safety announcement: FDA highlights importance of DPD deficiency discussions with patients prior to capecitabine or 5FU ...
The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) …